Drugs / CLBS03
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02691247 | Feb 2016 → Mar 2019 | type 1 diabetes mellitus | Lisata Therapeutics, Inc. | Completed | Missed primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CLBS03 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02691247 ↗ |
| Modality | Cell therapy | “A single infusion of CLBS03 Low Dose, a cell product comprised of autologous, ex vivo expanded regulatory T-cells resuspended in sterile USP (United States Pharmacopoeia)...” NCT02691247 ↗ |